

US Hemophilia Factor Brands by Company and Type

MANUFACTURER	RECOMBINANT			PLASMA-DERIVED		
	FVIII	FIX	Inhibitor	FVIII	FIX	Inhibitor
	Aptevo Therapeutics		Ixinity®			
Bayer	<i>Kogenate®FS</i> <i>Kovaltry®</i> <i>Jivi®</i>					
CSL Behring	<i>Afstyla®</i>	<i>Idelvion®</i>		Humate-P®	Mononine®	
Grifols				Alphanate	AlphaNine®S/D Profilnine®	
Kedrion*				Koate®-DVI		
Novo Nordisk	Novoeight®	<i>Rebiny®</i>	NovoSeven®RT			
Octapharma	Nuwiq®					
Pfizer	Xyntha®	BeneFix®				
Sanofi Genzyme	<i>Eloctate®</i>	<i>Alprolix®</i>				
Takeda	Advate <i>Adynovate</i> Recombinate	Rixubis		Hemofil M	Proplex-T	FEIBA VH

Italicized brand names indicate extended half-life products. Because there is no consensus on what constitutes an extended half-life product, check the package insert (PI) carefully. The half-life of a product may also vary widely from patient to patient, and may vary widely with age (younger=shorter half-life; older=longer half-life). Have a pharmacokinetic (PK) test to determine your individual factor half-life, and discuss with your HTC hematologist which product best meets your treatment needs.

Recombinate is a first-generation recombinant product. Kogenate FS is a second-generation product. Advate, Adynovate, Afstyla, Alprolix, BeneFix, Eloctate, Idelvion, Ixinity, Jivi, Kovaltry, Novoeight, Nuwiq, Rebiny, Rixubis, Vonvendi and Xyntha are third-generation products.

* Kedrion distributes Koate-DVI in the US for Grifols, which is the manufacturer.

Small-Molecule Hemophilia Therapies

Manufacturer	Product	Type	Indication
Genentech	Hemlibra®	Bispecific antibody (not a factor product). Administered subcutaneously weekly, biweekly or monthly.	Routine prophylaxis in adults and children with hemophilia A, with or without factor VIII inhibitors. Use of more than 100 U/kg total of aPCC (FEIBA®) for treating breakthrough bleeds increases risk of blood clots. Consult your healthcare provider before using FEIBA.

© 2019 LA Kelley Communications, Inc. All rights reserved.